treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
Published 10 months ago • 62 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
2:51
key btk inhibitor trials for the initial treatment of cll
-
1:18
involving the patient in treatment decisions for cll
-
1:28
the future of cll treatment
-
0:53
the future of cll treatment
-
0:45
key trials in cll and designing a concept for treatment
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
9:25
mgus diagnosis: a step-by-step approach
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:33
key factors affecting treatment decision making in cll
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:19
cll treatment: a look into the future
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
1:36
selecting the best treatment option in cll
-
1:48
do all patients require maintenance therapy following allosct?
-
2:08
impact of bridging therapy on the outcomes of patients with r/r myeloma treated with ide-cel
-
1:11
cll2-give trial: investigating chemotherapy-free treatment of cll
-
1:06
phase ib/ii study of viro-t-cell in patients with r/r cml infection after allosct
-
1:33
sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
-
1:11
integrating mrd data into treatment decisions in cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll